Boundless Bio
Health Care
$228.8Mraised in 3 rounds
200+people
11stories in the press
2018founded
People
Zachary Hornby
Director, Executive Officer
Benjamin Cravatt Ph.D.
Director
Scott Moorefield Ph.D.
Director
Chris Hassig Ph.D.
Director
Jason Christiansen Ph.D.
Director
Carolyn Ng Ph.D.
Director
Jonathan Lim M.D.
Director
Kristina Burow
Director
Ho Cho Ph.D.
Director
Jakob Loven Ph.D.
Director
Fabio Pucci Ph.D.
Director
Jennifer Lew
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
ARCH Venture PartnersVia a fund
Wellington ManagementVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified
Read more
Report
Boundless Bio to Participate in theGuggenheim Emerging Outlook: Biotech Summit 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified
Read more
Report
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
--Boundless Bio, a clinical-stage oncology company interrogating extrachromosomal DNA biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights
Read more
Report
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified
Read more
Report
Boundless Bio's Q3 2024: Advancing Cancer Therapies
Boundless Bio Inc. ( (BOLD) ) has released its Q3 earnings. Here is a breakdown of the information Boundless Bio Inc. presented to its investors.Boundless Bio Inc., a clinical-stage oncology company, focuses on developing therapies targeting extrachromoso
Read more
Report
Boundless Bio's 'BOLD' IPO Reels In $100M for a New Kind of Cancer Drug
Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.
Read more
Report
Startup Boundless Bio files to go public - San Diego's first life science IPO of 2024
Local life science startup Boundless Bio filed Wednesday to go public - the first San Diego biotech to do so this year. It is the first initial public offering, or IPO, by a local life science firm in the past four months, according to industry trade grou
Read more
Report
Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on ...
Read more
Report
Boundless Bio: Precision Oncology Company Secures $100 Million In Oversubscribed Series C Funding Round
Boundless Bio - a clinical-stage and next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers - announced the closing of a $100 million Series
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
La Jolla
United States
HQ
San Diego
United States
Regional office
See Location
10955 Alexandria Way, Suite 100, San Diego, CA 92121